Summary
Objective assessment of response in bone metastases from breast cancer using radiological techniques takes up to 6 months of treatment to be certain of a response, and sclerotic metastases are not evaluable. Standard serum and urinary tumour markers may not always be utilized to predict response, as they may not be elevated, and therefore may not change on treatment. The development of the urinary pyridinoline cross-link assays which measure mature bone breakdown products have been shown to be highly sensitive and specific as a measure of bone change in osteoporosis. We have measured pyridinoline (Pyr) and deoxypyridinoline (Dpyr) cross-links sequentially in 36 breast cancer patients with bone metastases, to determine if the measurement of these analytes predicts response at an earlier stage than radiological assessment. Response was assessed by UICC criteria. Seventeen women responded to hormonal therapy, whilst 19 developed progressive disease. Both Pyr and Dpyr increased sequentially in women with progressive disease with changes becoming apparent by 8 weeks (P < 0.03). In responding women, cross-link levels did not change significantly. Pyr and Dpyr were more sensitive and specific than the standard serum tumour marker CA 15-3. Urinary cross-link measurements provide a novel objective method of assessing response to treatment in women with bone metastases. Initial elevated urinary cross-link markers identify patients who tend not to respond to changes in hormonal therapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bettica, P., Moro, L., Robins, S. P., Taylor, J., Singer, F. R. & Baylink, D. J. (1992). Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin Chem 38: 2313–3218.
Coleman, R. E. & Rubens, R. D. (1987). The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61–66.
Coleman, R. E., Whittaker, K. B., Moss, D. W., Mashiter, G., Fogelman, I. & Rubens, R. D. (1988). Biochemical prediction of response of bone metastases to treatment. Br J Cancer 58: 205–210.
Coleman, R. E., Houston, S., James, I., Rodger, A., Rubens, R. D., Leonard, R. E. F. & Ford, J. (1992). Preliminary results of the use of urinary secretion of pyridinium cross links for monitoring metastatic bone disease. Br J Cancer 65: 766–768.
Colwell, A., Russell, R. G. G. & Eastell, R. (1993). Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 23: 341–349.
Delmas, P. D., Schlemmer, A., Gineyts, E., Riis, B. & Christiansen, C. (1991). Urinary excretion of pyridinium crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Min Res 6: 639–644.
Dodwell, D. J., Howell, A. & Ford, J. (1990). Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br J Cancer 61: 213–215.
Eastell, R., Hampton, L., Colwell, A. & Reeve, J. (1997). Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetics studies in osteoporosis. JBMR 12: 59–65.
Eyre, D. R. (1990). Editorial: New biomarkers of bone resorption. J Clin Endocrinol Metab 74: 470A–470C.
Fujimoto, D. (1980). Evidence for natural existence and pyridinoline crosslink in collagen. Biochem Res Commun 93: 948–953.
Hayward, J. L., Carbone, P. P., Henson, J. C., Kumaoka, S., Segaloff, A. & Rubens, R. D. (1977). Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289–1293.
Moro, L., Gazzarrini, C., Crivellari, D., Galligioni, E., Talamini, R. & de Bernard, B. (1993). Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem 39: 131–134.
Mundy, G. R., Ibbotsin, K. J. & D’Souza, S. M. (1985). Tumour products and the hypercalcaemia of malignancy. J Clin Invest 76: 391–394.
Paterson, C. R., Robins, S. P., Horobin, J. M., Preece, P. E. & Cuschieri, A. (1991). Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64: 884–886.
Peacock, M., Robertson, W. G. & Nordin, B. E. C. (1969). Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet i: 384–386.
Ratcliffe, W. A., Hutchensson, A. C. J., Bundred, N. J. & Ratcliffe, J. G. (1992). Role of assays for parathyroid hormone-related protein in investigation of hypercalcaemia. Lancet 339: 164–167.
Robertson, J. F. (1997). Letter. Eur J Cancer 33: 1774–1779.
Robertson, J. F., Pearson, D., Price, M. R., Selby, C., Blamey, R. W. & Howell, A. (1991). Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 64: 757–763.
Robins, S. P. (1982). Turnover and crosslinking in collagen. In Collagen in Health and Disease, Weiss JB Jayson MIV Churchill Livingstone: Edinburgh 160
Sano, M., Kyshida, K., Takahashi, M., Ohishi, T., Okada, M. & Inoue, T. (1994). Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer 70: 701–703.
Wada, S., Katayama, Y., Yasutomo, Y., Kugai, N. & Nagata, N. (1993). Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy. Intern Med 32: 611–618.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Walls, J., Assiri, A., Howell, A. et al. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 80, 1265–1270 (1999). https://doi.org/10.1038/sj.bjc.6690496
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690496
Keywords
This article is cited by
-
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622
Breast Cancer Research and Treatment (2016)